Journal of clinical immunology · 2025
Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Ming, Zhou Nian, Liang Qian, Lin Zhong, Yao Yanbing
Аннотация
BACKGROUND: IgA vasculitis (IgAV) is an autoimmune disorder characterized by inflammation of the small blood vessels. The pathogenesis of IgAV is believed to involve a complex interplay between immune cells, metabolites, and inflammatory cytokines (ICs).
METHODS: We performed two-sample Mendelian randomization (MR) analysis to examine the causal relationship between immune cell traits, metabolites, ICs, and IgAV. Genetic variants associated with exposure, mediators and outcome were extracted from large-scale genome-wide association studies (GWAS). The inverse variance weighted (IVW) method was used as the primary approach, supported by MR Egger, weighted median, simple mode, and weighted mode methods.
RESULTS: In this study, we identified 25 immune cells, 6 metabolites (Threonate, Carnitine C5:1, Chiro-inositol, Carnitine C18:2, 3-formylindole, Cholate to phosphate ratio) and 2 ICs (T - cell surface glycoprotein CD5, Osteoprotegerin) associated with IgAV. Meanwhile, we identified 5 immune cell-metabolites-IgAV pathways (CD28+CD45RA-CD8dim AC-3-formylindole-IgAV; CD28+ CD45RA- CD8dim AC-Cholate to phosphate ratio-IgAV; CD28+ CD45RA+ CD8br%T cell-3-formylindole-IgAV; CD25 on IgD+ CD38- unswmem-Chiro-inositol- IgAV; HLA DR on CD14+ CD16- monocyte-Chiro-inositol-IgAV; CD39+ secreting Treg %secreting Treg-Threonate-IgAV) and 4 immune cells-ICs-IgAV pathways (IgD- CD38- AC-Osteoprotegerin-IgAV; CD45 on T-Osteoprotegerin-IgAV; HLA DR on CD14+ CD16- monocyte-CD5-IgAV; HLA DR on CD14+CD16- monocyte-CD5-IgAV).
CONCLUSIONS: These results highlight the need for further research to investigate the underlying mechanisms and identify potential therapeutic targets for the treatment of IgAV.
METHODS: We performed two-sample Mendelian randomization (MR) analysis to examine the causal relationship between immune cell traits, metabolites, ICs, and IgAV. Genetic variants associated with exposure, mediators and outcome were extracted from large-scale genome-wide association studies (GWAS). The inverse variance weighted (IVW) method was used as the primary approach, supported by MR Egger, weighted median, simple mode, and weighted mode methods.
RESULTS: In this study, we identified 25 immune cells, 6 metabolites (Threonate, Carnitine C5:1, Chiro-inositol, Carnitine C18:2, 3-formylindole, Cholate to phosphate ratio) and 2 ICs (T - cell surface glycoprotein CD5, Osteoprotegerin) associated with IgAV. Meanwhile, we identified 5 immune cell-metabolites-IgAV pathways (CD28+CD45RA-CD8dim AC-3-formylindole-IgAV; CD28+ CD45RA- CD8dim AC-Cholate to phosphate ratio-IgAV; CD28+ CD45RA+ CD8br%T cell-3-formylindole-IgAV; CD25 on IgD+ CD38- unswmem-Chiro-inositol- IgAV; HLA DR on CD14+ CD16- monocyte-Chiro-inositol-IgAV; CD39+ secreting Treg %secreting Treg-Threonate-IgAV) and 4 immune cells-ICs-IgAV pathways (IgD- CD38- AC-Osteoprotegerin-IgAV; CD45 on T-Osteoprotegerin-IgAV; HLA DR on CD14+ CD16- monocyte-CD5-IgAV; HLA DR on CD14+CD16- monocyte-CD5-IgAV).
CONCLUSIONS: These results highlight the need for further research to investigate the underlying mechanisms and identify potential therapeutic targets for the treatment of IgAV.